07:00 , Apr 21, 2008 |  BC Week In Review  |  Clinical News

Farletuzumab regulatory update

The EC granted Orphan Drug designation to Eisai's farletuzumab to treat ovarian cancer. The humanized IgG1 antibody against glycoprotein-3 (GP-3) is in Phase II testing in patients with platinum sensitive ovarian cancer. Eisai obtained...
07:00 , Mar 26, 2007 |  BC Week In Review  |  Company News

Morphotek, Eisai deal

Eisai bolstered its oncology portfolio last September by acquiring the cancer product line of Ligand Pharmaceuticals Inc. (LGND, San Diego, Calif.) (see BioCentury, Sept. 11, 2006). Eisai also has E7389, a synthetic analog...
07:00 , Mar 26, 2007 |  BioCentury  |  Strategy

Building a cancer pipeline

Building a cancer pipeline Compound Description Indication Status Eisai E7389 Synthetic analog of halichondrin B Breast Ph III E7070 Cell cycle G1 phase-targeting agent Small cell lung Ph I E7820 Anti-angiogenesis agent Various Ph I...
01:32 , Mar 23, 2007 |  BC Extra  |  Top Story

Eisai to acquire Morphotek

Eisai (Tokyo:4523; Osaka:4523) will acquire antibody company Morphotek (Exton, Penn.) for $325 million in cash. Morphotek estimates it will return about $25 million in cash to shareholders, bringing the total deal value to about $350...